A phase II trial of ImmunotheRapy with single fRactIon non-ablative raDIAtion in previously untreated patients with stage IV NSCLC. (IRRIDIATE-Lung trial)
Brief description of study
This is a phase II open label trial of pembrolizumab sequentially following upfront non-ablative focal therapy to up to five distinct metastatic subsites in de novo stage IV Non-Small Cell Lung Cancer (NSCLC). The primary goal of this trial is to evaluate the efficacy of upfront non-ablative focal radiation (RT) to index lesions as a way of enhancing the anti-tumor immune response to pembrolizumab.
Clinical Study Identifier: s22-00673
ClinicalTrials.gov Identifier: NCT05691829
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.